Eligibility for Endovascular Trial Enrollment in the 6- to 24-Hour Time Window [Brief Report]
Conclusions—Of all patients with acute ischemic stroke presenting to a single comprehensive stroke center, 1.7% of patients qualified for DAWN clinical trial enrollment with an additional 0.6% to 1% qualifying for the DEFUSE-3 trial. These data predict an increase in thrombectomy utilization with important implications for comprehensive stroke center resource optimization and stroke systems of care.
Source: Stroke - Category: Neurology Authors: Ashutosh P. Jadhav, Shashvat M. Desai, Cynthia L. Kenmuir, Marcelo Rocha, Matthew T. Starr, Bradley J. Molyneaux, Bradley A. Gross, Brian T. Jankowitz, Tudor G. Jovin Tags: Cerebrovascular Disease/Stroke, Cerebrovascular Procedures, Ischemic Stroke Brief Reports Source Type: research
More News: Brain | Clinical Trials | Computers | Ischemic Stroke | Neurology | Perfusion | Stroke | Study